Budiman Bela

AIDS Vaccine for Asia Network (AVAN): Expanding the Regional Role in Developing HIV Vaccines

Yiming Shao and colleagues describe the work of AVAN, the AIDS Vaccine for Asia Network, which aims to strengthen its regional efforts in finding an AIDS vaccine.

Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia

An important meeting titled “Defining the Objectives of the AIDS Vaccine Asian Network (AVAN)” was held 22–24 February 2009, in Beijing. This report describes the outcomes of this meeting. The meeting was jointly organised by the World Health Organization (WHO), the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the Global HIV Vaccine Enterprise (GHVE) Regional Consultation on Expanding AIDS Vaccine Research and Development Capacity in Asia. Sixty-eight participants (Supplementary Digital Content 1) and observers gathered together from 16 countries including Australia, Cambodia, China, France, India, Indonesia, Japan, the Netherlands, the Philippines, the Russian Federation, Singapore, Sweden, Switzerland, Thailand, the United States of America and Viet Nam. The meeting was highly relevant for the Asian region at a time when the HIV epidemic is still rampant despite concerted efforts by governments, communities, scientists and key stakeholders to stem its impact and advance. A great deal of work has been undertaken towards an AIDS vaccine over the past 15 years and the region has the essential assets to move the agenda forward. Genesis of the 2009 Beijing meeting In 1998, the first Asian meeting specifically devoted to AIDS vaccine research and development was convened by WHO-UNAIDS and the Japanese National Institute of Infectious Diseases (NIID) in Tokyo, Japan. In 2006, the regional strategy concept was revisited at the first WHO-UNAIDS regional consultation, Expanding Capacity and Accelerating AIDS Vaccine Development in Asia, hosted and co-organized by the University of Hokkaido, Sapporo, Japan. The 7 recommendations of the 2006 Sapporo meeting were to: First, create forums to facilitate interactions between funders and discuss funding opportunities, funding streams and funder capabilities. Second, facilitate linkages between research and development (R&D), innovation and discovery, in particular in emerging countries with strong innovation capacity, such as China, India and Thailand, and clinical trial capacity and production. Third, provide a forum for coordination of regional expertise, capacity building, and technical assistance. Fourth, promote advocacy and communication support for region-specific strategies. Fifth, contribute to and promote the implementation of the Scientific Strategic Plan of the GHVE. Sixth, prepare for future deployment of a vaccine by discussing regional approaches to ensure access, delivery capacity, demand estimates, epidemiology, vaccine characteristics, and strategies for delivery. Seventh, create a regional harmonization or regional authority for regulatory interactions, including regional licensure review and regional ethics committees with an initial ‘core’ working group. To effectively implement and further facilitate the recommendation to develop an ongoing forum for coordination of regional expertise, capacity building and technical assistance, the establishment of AVAN was proposed. In February 2009, the Chinese AIDS Vaccine Initiative (CAVI), GHVE and WHO-UNAIDS convened a follow-up meeting in Beijing, China to speed up implementation of recommendations of the Sapporo consultation.

The effect of an Annona muricata leaf extract on nutritional status and cytotoxicity in colorectal cancer: a randomized controlled trial.

BACKGROUND AND OBJECTIVES Annona muricata leaf infusion has traditionally been consumed to maintain health, but is now considered for use in treating cancer patients. The objective of this study was to elucidate the effects of A. muricata leaf extract in humans and human cell lines. METHODS AND STUDY DESIGN Thirty outpatients with colorectal cancer who had undergone primary tumor resection were enrolled in a randomized double-blind placebo- controlled pre-post-trial. They were divided into two groups: those who ingested A. muricata leaf extract (n=14) and those who ingested a placebo (n=14) daily for 8 weeks. Twenty-eight subjects completed the trial; they were equally distributed between the two groups. Serum from patients of both groups was compared for cytotoxicity against colorectal cancer cell lines. The nutritional status of patients was monitored throughout the study. RESULTS Ex vivo and clinical studies showed higher cytotoxicity in the supplemented group compared with the placebo group. Further research is required to investigate the long-term effect of A.muricata leaf extract, particularly on parameters directly related to cytotoxic activity toward colorectal cancer cells and nutrition status.